Intranasal administration of TAT-haFGF(14-154) attenuates disease progression in a mouse model of Alzheimer's disease
Bibliographic
Year of Publication:
2012
Contact PI Name:
Y. Huang
Primary Reference (PubMED ID):
Funding Source:
National Science and Technology Major Project of China
Study Goal and Principal Findings:
This study aimed at testing the efficacy of the the fusion protein TAT-haFGF 14-154 in ameliorating AD-related phenotype of the SAMP8 AD mouse model.. Data showed that the intranasal administration of modified TAT-haFGF recombinant protein successfully reached the brain,. significantly improved the learning and memory abilities of SAMP8 mice and ameliorated the function of the cholinergic system. In addition, TAT-haFGF14–154 significantly reduced Abeta 1–42 deposits, reduced the levels of Abeta soluble forms, protected the neurons from apoptosis and alleviated the oxidative stress markers observed in the brain and serum. These results suggest that TAT-haFGF14-154 may be a viable disease-modifying treatment for AD.
Therapeutic Agent
Therapeutic Information:
Therapy Type:
Biologic - Peptide
Therapeutic Target:
Fibroblast Growth Factor Receptor (FGFR)
Animal Model
Model Information:
Species:
Mouse
Model Type:
Accelerated Aging
Model Name:
SAMP8
Strain/Genetic Background:
Not Reported
Experimental Design
Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest
Outcomes
Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Step-Down Passive Avoidance Test
Histopathology
beta Amyloid Load
Biochemical
Cholinergic Markers
Brain-beta Amyloid Oligomers
Oxidative Stress Markers
Cell Biology
Apoptosis
Pharmacokinetics
Drug Concentration-Brain
Recombinant Protein Concentration-Liver